Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)

• Status: Completed
• Trial end date: 2004-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the bioequivalence of the losartan/hydrochlorothiazide (HCTZ) combination tablet and coadministration of losartan and hydrochlorothiazide.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Hydrochlorothiazide; Losartan

Criteria

Inclusion Criteria:

• Subject is a healthy male or female between the ages of 18 and 45 years of age

• Subject does not smoke

Exclusion Criteria:

• Subject has a history of any illness that might pose additional risk to participation or confound the results of the study

• Subject has a history of hepatitis B or C or significant drug allergies